AlphaQuest LLC Boosts Stock Position in LeMaitre Vascular, Inc. $LMAT

AlphaQuest LLC raised its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 155.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,521 shares of the medical instruments supplier’s stock after purchasing an additional 16,744 shares during the quarter. AlphaQuest LLC’s holdings in LeMaitre Vascular were worth $2,232,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue grew its stake in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 147 shares during the last quarter. Johnson Investment Counsel Inc. boosted its stake in shares of LeMaitre Vascular by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after buying an additional 153 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after buying an additional 155 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of LeMaitre Vascular by 2.2% in the third quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock worth $630,000 after buying an additional 158 shares during the last quarter. Finally, Illinois Municipal Retirement Fund boosted its stake in shares of LeMaitre Vascular by 1.6% in the third quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock worth $967,000 after buying an additional 171 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insiders Place Their Bets

In other news, CEO George W. Lemaitre sold 150,000 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total value of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares of the company’s stock, valued at $163,588,775.04. This represents a 8.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 269,891 shares of company stock worth $28,969,086. Company insiders own 7.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wells Fargo & Company upped their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Roth Mkm restated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Citizens Jmp upped their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings upgraded LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 20th. Finally, Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $98.71 on Wednesday. LeMaitre Vascular, Inc. has a one year low of $79.00 and a one year high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The stock has a market cap of $2.26 billion, a PE ratio of 36.42, a P/E/G ratio of 2.72 and a beta of 0.60. The stock has a 50 day moving average price of $108.17 and a 200 day moving average price of $95.53.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter last year, the firm earned $0.48 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is 36.90%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.